Parry Christopher M, Taylor Andrew, Williams Ruby, Lally Hayley, Corbett Harriet J
NIHR Alder Hey Clinical Research Facility, East Prescot Road, Liverpool, UK.
Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Eur J Pediatr. 2023 Sep;182(9):4087-4093. doi: 10.1007/s00431-023-05087-w. Epub 2023 Jul 4.
Continual antibiotic prophylaxis (CAP) can reduce the risk of recurrent UTI (rUTI). However, antimicrobial resistance in subsequent UTIs is a concern. This study aimed to explore antimicrobial resistance in young children prescribed CAP for rUTIs. A retrospective review of patient records/microbiology results was undertaken for children < 2 years of age, on CAP, with 2-3 clean catch/mid-stream/supra-pubic aspirate urine cultures with a pure growth of bacteria, between January 2017 and December 2019. One hundred twenty-four urine specimens from 54 patients (26 (48%) males, median age 6 months) were analysed. CAP prescribed was trimethoprim in 37 (69%), cefalexin in 11 (29%), and nitrofurantoin in 6 (11%). Based on antimicrobial susceptibility of the index UTI within the study period, 41 patients (76%) grew organisms on urine culture classified as sensitive and 13 (24%) resistant. Thirty-five (65%) children had congenital anomaly of the kidneys and urinary tract (CAKUT); they were more likely to be in the resistant group (P = 0.032). Escherichia coli (37/54, 69%) was the commonest index uropathogen. The resistant group had a higher proportion of non-E. coli index UTI pathogens (P = 0.098). Breakthrough UTI with a CAP-resistant organism was more likely in the resistant group (P = 0.010). Age, sex, and kidney scarring on DMSA (dimercaptosuccinic acid) scan were not significantly different between groups. Conclusion: Over a 3-year period, the proportion of children on CAP with resistant organism UTI doubled and resistant infections were more likely in children with CAKUT. Development of non-antimicrobial prophylaxis options is required. What is Known: • Recurrent urinary tract infections are common in children, particularly in those with underlying anatomical abnormalities of the kidneys and urinary tract. • Continuous antibiotic prophylaxis is used frequently in these children, however there is a lack of consensus on whether the potential benefits of CAP outweigh the harms. What is New: • This study adds further evidence towards the consequences of using continuous antibiotic prophylaxis in recurrent UTI; specifically, a 2-fold increase in antimicrobial resistance was seen in subsequent UTIs following long-term use of CAP, providing further vigour for the need for non-antibiotic alternatives.
持续抗生素预防(CAP)可降低复发性尿路感染(rUTI)的风险。然而,后续尿路感染中的抗菌药物耐药性是一个令人担忧的问题。本研究旨在探讨因rUTI而接受CAP治疗的幼儿中的抗菌药物耐药性。对2017年1月至2019年12月期间年龄小于2岁、正在接受CAP治疗、有2 - 3次清洁中段尿/耻骨上穿刺尿培养且细菌纯培养生长的儿童的病历/微生物学结果进行了回顾性分析。对54例患者(26例(48%)为男性,中位年龄6个月)的124份尿液标本进行了分析。所开具的CAP中,37例(69%)为甲氧苄啶,11例(29%)为头孢氨苄,6例(11%)为呋喃妥因。根据研究期间首次尿路感染的抗菌药物敏感性,41例患者(76%)尿培养中生长的微生物被分类为敏感,13例(24%)为耐药。35例(65%)儿童有先天性肾脏和尿路异常(CAKUT);他们更有可能属于耐药组(P = 0.032)。大肠埃希菌(37/54,69%)是最常见的首发尿路病原体。耐药组中非大肠埃希菌首发尿路感染病原体的比例更高(P = 0.098)。耐药组中更有可能发生对CAP耐药菌的突破性尿路感染(P = 0.010)。两组之间在年龄、性别以及二巯基丁二酸(DMSA)扫描显示的肾瘢痕方面无显著差异。结论:在3年期间,接受CAP治疗且感染耐药菌的儿童比例增加了一倍,CAKUT儿童发生耐药感染的可能性更大。需要开发非抗菌预防方案。已知信息:• 复发性尿路感染在儿童中很常见,尤其是那些有潜在肾脏和尿路解剖异常的儿童。• 这些儿童经常使用持续抗生素预防,然而对于CAP的潜在益处是否超过危害缺乏共识。新发现:• 本研究进一步证明了在复发性尿路感染中使用持续抗生素预防的后果;具体而言,长期使用CAP后,后续尿路感染中的抗菌药物耐药性增加了两倍,这为需要非抗生素替代方案提供了进一步的有力证据。